This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): somatropin [rDNA origin] for injection, r-HGH, Zorbtive
Description: Serostim is a human growth hormone, identical in structure do the dominant form secreted by the pituitary. It is an anabolic and anticatabolic agentwhich exerts its influence by interacting with specific receptors on a variety of cell typesincluding myocytes, hepatocytes, adipocytes, lymphocytes, and hematopoietic cells.Some, but not all of its effects, are mediated by insulin-like growth factor-I (IGF-I).
Zorbtive is Merck KGaA's trade name for this recombinant human growth hormone indicated for short bowel syndrome (SBS).
Deal Structure: In January 2007, the acquisition of Serono S.A. (now Merck Serono S.A.) by Merck KGaA and the integration of the business with the former Merck KGaA Ethicals Division was completed. Merck Serono is now the division of Merck KGaA which specializes in prescription pharmaceuticals. Its North American business operates in the United States and Canada under EMD Serono.
Pink Sheet In Brief: Serono Serostim
Pink Sheet In Brief: Serono's Serostim
Additional information available to subscribers only: